BTIG Reaffirms Buy Rating on MDxHealth, Increases Price Target to $7
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDXH
Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.560
Low
7.00
Averages
7.67
High
9.00
Current: 3.560
Low
7.00
Averages
7.67
High
9.00
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MDxHealth Reports $109M Revenue for 2025, Projects 26%-28% Growth for 2026
- Significant Revenue Growth: MDxHealth expects fourth-quarter 2025 revenue of approximately $30.5 million, a 23% increase from $24.7 million in Q4 2024, indicating continued double-digit growth across its precision diagnostics portfolio.
- Full-Year Performance Boost: Projected full-year revenue for 2025 is $109 million, up 21% from $90 million in 2024, reflecting strong market performance and increased customer demand.
- Successful Product Transition: In 2025, the company sold 71,920 liquid-based units, a 57% increase, while tissue-based units totaled 49,180, up 18%, demonstrating the successful integration of the Exosome Diagnostics business.
- Optimistic Future Outlook: MDxHealth issued 2026 revenue guidance of $137 million to $140 million, representing expected growth of 26% to 28%, while aiming for a 10% adjusted EBITDA margin run rate by the end of 2026, showcasing confidence in sustained growth.
Continue Reading
MDxHealth Files Shelf Registration to Sell Up to $200 Million in Shares
- Financing Plan: MDxHealth has filed a shelf registration to sell up to $200 million in shares, including $50 million in preferred stock, aimed at strengthening the company's capital structure to support future growth.
- Market Reaction: This stock issuance plan may influence investor perceptions of the company's future financial health, potentially leading to short-term stock price volatility, but ultimately enhancing liquidity in the long run.
- Strategic Significance: By raising funds, MDxHealth can increase investments in research and development, particularly in the precision medicine sector, thereby enhancing its market competitiveness and driving business expansion.
- Investor Focus: The market will closely monitor the specific uses of this financing and its potential impact on the company's future performance, especially in the context of increasing competition in the healthcare industry.
Continue Reading